Be Biotechnologies is a biopharmaceutical, founded on cannabinoid and plant-based research, development, and Evidence-based drug development (EBD), aimed at transforming knowledge from biopharmaceutical sciences into new pharmaceutical drugs for animals and humans. Be Biotechnologies is working on developing evidence-based plant-based drug candidates that provide solutions to unmet medical needs. The company is using a decentralized development model, powered by AI, to accelerate the drug development process. Let’s explore how Be Biotechnologies is transforming knowledge into evidence-based plant-based drug development.
Evidence-Based Drug Development
Be Biotechnologies is using evidence-based drug development (EBD) to develop new pharmaceutical drugs for animals and humans. For EBD, the R&D team is working with several internal researchers and collaborating around the world, using a decentralized development model. They are using a cloud lab to develop the drug candidates, increase experimental output, repeat the past work, or deepen the analysis at the push of a button. A board of curators and biomedical experts evaluates all the work, analysis of the new drug candidate using the advantage of artificial intelligence. This approach focuses on intellectual contribution instead of manual labor, enabling the company to accelerate the drug development process.
Plant-Based Drug Candidates
Be Biotechnologies is working on developing evidence-based plant-based drug candidates that provide solutions to unmet medical needs in dermatology, anti-oxidant boosters for astronauts, chronic pain, and various neurological diseases, providing patients access to more affordable and modern phyto-pharmaceutical treatments after regulatory clearance in each territory. The company has developed over 20 different formulations for the development of commercial products, including cosmetics, wellness, and pharmaceuticals, besides the global distribution of APIs/RAW materials.
Microgravity Plant Science in Space
Be Biotechnologies aims to become the hub for microgravity plant science in space, understanding the three-dimensional structure of proteins is critical to life science and biopharmaceutical researchers. This information can be used for understanding disease mechanisms, identifying drug targets, and optimizing pharmaceutical drug design. In partnership with NASA and ESA implementation partners, Be Biotechnologies wants to create the opportunity to deepen their drug development knowledge.
Be Biotechnologies powered by AI
Be Biotechnologies is powered by AI, enabling the company to accelerate the drug development process, improve efficiency, and reduce costs. The company’s decentralized development model, powered by AI, is enabling them to develop evidence-based plant-based drug candidates faster, enabling patients to access affordable and modern phyto-pharmaceutical treatments after regulatory clearance in each territory.
Be Biotechnologies is a startup that is revolutionizing the biopharmaceutical industry by using evidence-based drug development to develop new pharmaceutical drugs for animals and humans. The company is working on developing evidence-based plant-based drug candidates that provide solutions to unmet medical needs, and they are powered by AI, enabling them to accelerate the drug development process. With their focus on microgravity plant science in space, Be Biotechnologies is contributing to the advancement of biopharmaceutical research. It’s a startup to watch out for in the future.
Website: http://www.bebiotechnologies.com
Twitter: http://www.twitter.com/bebiotech
Facebook: http://www.facebook.com/bebiotechnologies
LinkedIn: https://www.linkedin.com/company/be-biotechnologies
Ready to amplify your reach and engage with the most dynamic community in the venture world? Consider sponsoring an article with us. Learn more about our promotional opportunities and sponsored articles here.
Your story could be the next big hit on US Venture News!
Follow Us